A man with a prolactin secreting pituitary carcinoma was treated by surgery and radiotherapy. Persistent hyperprolactinaemia partially responded to oral bromocriptine for four years. Serum prolactin then rose considerably with rapid, invasive tumour recurrence. Cytotoxic chemotherapy halted tumour progression for twelve months before fatal spread throughout the brain. Failure to normalise serum prolactin with bromocriptine may precede an aggressive course in patients with prolactinoma. (surgery,3 " radiotherapy5 and chemotherapy) is then unclear.
A 40 year old man presented in 1979 with headache and a left paracentral scotoma. CT scan showed a large pituitary neoplasm with suprasellar extension (figure). Preoperative endocrine assessment showed hyperprolactinaemia (serum prolactin greater than 4000 mU/L, normal range < 400 mU/L) and panhypopituitarism. Frontal craniotomy and sub-total removal of the tumour was performed with recovery of vision. Histology showed the basic architecture of a pituitary adenoma which was highly cellular and demonstrated mitotic activity. Immunohistochemistry (DAKO polyclonal antibodies) showed intense staining for prolactin, but for all other hormones was negative (ACTH, FSH, LH, GH, TSH).
Replacement therapy was started (hydrocortisone, thyroxine and sustanon 250 mgs) and radiotherapy given (4800 rads, 20 fractions, 29 days). One month after radiotherapy there was a further bilateral reduction in visual acuity. CT scan showed a large suprasellar cyst which was drained with subsequent recovery of vision ( figure) .
In 1980 oral bromocriptine therapy (20 mgs a day) was started to control hyperprolactinaemia (greater than 4000 mU/L). Over the next three years there was no clinical or radiological evidence of tumour recurrence although there was incomplete suppression of serum prolactin levels (500-1800 mU/L). In 1984 bromocriptine dose was increased (40 mgs a day) following a further elevation of the serum prolactin (greater than 4000 mU/L). Eight months later there was further visual disturbance. CT scan showed tumour recurrence with marked supero-lateral extension. Serum prolactin was 81 000 mU/L despite bromocriptine 40 mgs daily. Transfrontal decompression and subtotal removal of tumour produced a transient recovery but within one year there was further bilateral deterioration in visual acuity. CT scan showed another large tumour recurrence with extension towards the internal carotid bifurcation and into the middle cranial fossa (serum prolactin 19000 mU/L; bromocriptine 40 mgs daily). Further transfrontal decompression proved ineffective. Tumour histology on this occasion demonstrated a more pleomorphic tumour which was invading overlying cerebral tissue. A full course of cytotoxic chemotherapy (CCNU; procarbazine; etoposide x 4 cycles) was given with marked improvement of vision. Serial CT scans over 12 months showed no evidence of further invasive tumour spread (serum prolactin 17 000 mU/L; bromocriptine 40 mgs daily).
In 1987 there was a sudden marked elevation of serum prolactin level (greater than 42 000 mU/L). CT scan showed extensive tumour spread into the right cavernous sinus and right retro-orbital space. A combination of transfrontal decompression and further cytotoxic chemotherapy (1 cycle pre-op; 4 cycles post-op) failed to prevent further tumour progression.
There was a subsequent marked clinical deterioration with further visual loss, right sided cranial nerve involvement (3rd to 6th) and marked hyperprolactinaemia (500 000 mU/L). The 
